BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib are currently the
standard treatment for metastatic melanoma with BRAF V600 mutations. However, given the …

The majority of patients with melanoma harbor mutations in the BRAF oncogene, thus
making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) …

Background Selective BRAF inhibitors have shown dramatic results with regard to improving
outcome in patients with melanoma. Testing the BRAF status in matched primary and …

Multiple mechanisms have been described that confer BRAF inhibitor resistance to
melanomas, yet the basis of this resistance remains undefined in a sizable portion of patient …

Background BRAF mutant melanoma treated with BRAF±MEK inhibitor (targeted therapy)
has a high response rate; however, most patients progress (PD). Some patients have …

Approximately 50% of patients with cutaneous metastatic melanoma harbor a somatic BRAF
mutation. BRAF inhibitors are now established in the treatment paradigm of BRAF mutant …

Historically, patients with advanced cutaneous melanoma have a poor prognosis and limited
treatment options. The discovery of selective v-raf murine sarcoma viral oncogene homolog …

Over half of BRAFV600E melanomas display intrinsic resistance to BRAF inhibitors, in part
due to adaptive signaling responses. In this communication we ask whether BRAFV600E …

Abstract The RAS/RAF/MEK/ERK pathway has been reported to be activated in over 80% of
all cutaneous melanomas, making it the focus of many scientific studies in the melanoma …

Genetic analysis of melanoma has allowed us to identify a population of patients who have
more aggressive disease and harbor the driver mutation BRAF. This mutation is found in …